Samumed, United Therapeutics Announce North American License Agreement For Samumed's IPF Drug Candidate; Deal Includes $10M Up-Front Plus Up To $340M In Developmental Milestones And Up To Low Double-Digit Royalties
Benzinga_Newsdesk